Delivering quality therapy since 1901
  • Press releases

    European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia

    ​Gedeon Richter Plc. ("Richter") announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the company's application for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. The marketing authorization application has been submitted to EMA in March 2016. Subject to approval by the European Commission, Richter is expected to receive in two months a marketing authorization for cariprazine valid for all European Union Member States.

  • in Focus

    Gynaecology

    Gynaecological therapy is a focus area for Richter. The company has several decades of unparalleled experience in this area. The first steroid experiments were conducted by the company’s founder, Gedeon Richter himself. Our company was the first pharmaceutical company to put a contraceptive on the Hungarian market, in 1966.

  • Central Nervous System
  • Cardiology
Loading...

​​​​​ ​​​​​ ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​